RDEA119 and Sorafenib Combination Dose Escalation Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Advanced Cancer
Interventions
DRUG

RDEA119

Total daily doses of RDEA119 from 10 mg/day to 100 mg/day

DRUG

Sorafenib

Total daily doses of sorafenib from 400 mg/day to 800 mg/day.

Trial Locations (10)

12206

New York Oncology Hematology, PC, Albany

14263

Roswell Park Cancer Institute, Buffalo

14642

James P. Wilmot Cancer Center, Rochester

19104

UPenn, Philadelphia

29605

Greenville Hospital System University Medical Center, (ITOR), Greenville

75246

Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas

75702

Texas Oncology-Tyler, Tyler

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90033

USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center, Los Angeles

M5G 2N2

Toronto General Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY